← Back to Clinical Trials
Recruiting Phase 2 NCT05357066

Nitrous Oxide as Treatment for Fibromyalgia

Trial Parameters

Condition Fibromyalgia
Sponsor University of Chicago
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 50
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2021-11-12
Completion 2027-06-01
Interventions
Nitrous oxide gas for inhalationPlacebo

Brief Summary

The purpose of this study is to explore a potential role of nitrous oxide in treating pain associated with fibromyalgia.

Eligibility Criteria

Inclusion Criteria: * 2016 American College of Rheumatology Revised criteria for fibromyalgia (2016-ACR) * Subjects 18 -75 years of age. * Self-reported pain of at least 4 on the Numeric Pain Rating Scale (NPRS) at screening and baseline. * Subject receives and agrees to remain on their stable fibromyalgia treatment plan established at least 4 weeks prior to dosing. Stable means no change in dose or any pain medication. * Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments * If currently on psychotherapy, it must have been maintained at the same frequency for 4 weeks prior to treatment. Exclusion Criteria: * Unstable doses of allowed antidepressants or muscle relaxants or dosages for any other medical condition. * Pain due to concurrent autoimmune or inflammatory disease such as rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, or other chro

Related Trials